The future of Point of Care Analysis – Right Here, Right Now
Prolight Diagnostics has developed a breakthrough point-of-care system that delivers reliable test results in 10 minutes or less, right at the patient´s side. Driving efficiency and accelerating time to clinical decision. Watch the video (https://youtu.be/WVNC8vKRdWA) to discover why our proprietary, patent-protected technology is at the heart of the next major shift in healthcare. For further information, please […]
Prolight announces additional subscription commitments and a lock-up commitment for upcoming rights issue of shares
Prolight Diagnostics (“Prolight” or the “Company”) hereby announces that additional existing shareholders and external investors have submitted subscription commitments totaling 2.9 MSEK for the upcoming rights issue of shares (the “Rights Issue”) that Prolight resolved on, subject to approval by the subsequent extraordinary general meeting, on May 21, 2025. Including these new subscription commitments, the […]
Prolight Diagnostics AB (publ) publishes annual report for 2024
Prolight Diagnostics AB (publ) announces that the annual report for 2024 is now available on the company’s website: https://prolightdx.com/en/investors/financial-reports/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic […]
Prolight Diagnostics publishes quarterly report Q1, 2025
Financial overview First quarter, January 1 – March 31, Q1 2025 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 1,662 (68) thousand SEK. Profit after tax amounted to -10,937 (-8,929) thousand SEK. Earnings per share before and after dilution: -0.02 […]
Biostock publishes article about the positive pre-clinical results and coming milestone for Prolight Diagnostics in Q2
Prolight’s CSO reflects on positive pre-clinical results and looks ahead to the next key milestone in Q2: Read the article here: https://biostock.se/2025/05/prolights-cso-reflects-on-positive-pre-clinical-results-and-looks-ahead-to-key-milestone-in-q2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing […]
NOTICE OF THE ANNUAL GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), corp. reg. no. 556570-9499, (the ”Company”) are hereby notified of the annual general meeting to be held on Monday 30 June 2025 at 1 p.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification of attendance Shareholders who wish to participate in the annual general […]
Emergers publishes updated analysis about Prolight Diagnostics
Emergers publishes updated analysis about Prolight DIagnostics with the title: ”Gearing up for commercialisation with strong insider backing”. Among others, the article describes ”Strong insider commitment signals confidence” and that Prolight is ”Well-positioned for strategic partnering in 2025” Read the article here: https://www.emergers.se/prolight-j25/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: […]
NOTICE OF EXTRAORDINARY GENERAL MEETING IN PROLIGHT DIAGNOSTICS AB (PUBL)
The shareholders in Prolight Diagnostics AB (publ), reg. no. 556570-9499, (the ”Company”) are hereby convened to the extraordinary general meeting to be held on Tuesday 10 June 2025 at 10 a.m. at the Company’s office, Gasverksgatan 3 A, 222 29 Lund, Sweden. Notification etc.Shareholders who wish to participate in the extraordinary general meeting must:– be […]
Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]
Prolight receives new MicroFlex patent approval in the US
Prolight announces today that the US Patent and Trademark Office (USPTO), pursuant to the notice of allowance issued on March 26, has granted Prolight a patent for the analytical unit and reaction chamber for the company’s point-of-care analysis system, MicroFlex, which is being developed by Prolight’s partner TTP (The Technology Partnership plc). This patent complements the […]
